KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE).

Max Kates, Xiangying Chu, Noah Hahn, Eugene Pietzak, Angela Smith, Daniel H Shevrin, Paul Crispen, Stephen B Williams, Siamak Daneshmand, Vignesh T Packiam, Sima Porten, Mary E Westerman, Lynne I Wagner, Michael Carducci

Eur Urol Focus 9(4) 561-563

PMID37422371
PMCIDPMC10515442
DOI10.1016/j.euf.2023.06.006
发表日期2023-07-08
摘要

摘要

EA8212 BRIDGE is a phase 3 randomized trial comparing BCG vs GemDoce for BCG naïve high-risk non-muscle-invasive bladder cancer. This article provides an explanation for the rationale of the clinical trial and details the study design.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。